Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wentao Fu

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2016
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerAmanda J Walker, Suparna Wedam, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal CancerSandra J Casak, M Naomi Horiba, Mengdie Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial CarcinomaMichael H Brave, William F Maguire, Chana Weinstock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2018
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast CancerAnand Shah, Erik Bloomquist, Shenghui Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2018
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid LeukemiaAviva C Krauss, Xin Gao, Liang Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2024
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal CancerMichael J Fusco, Sandra J Casak, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2020
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Sakar Wahby, Jennifer J Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2024
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, <i>ESR1</i>-Mutated Advanced or Metastatic Breast CancerMirat Shah, Hima Lingam, Xin Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2022
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLCOladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2016
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerAmanda J Walker, Suparna Wedam, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal CancerSandra J Casak, M Naomi Horiba, Mengdie Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial CarcinomaMichael H Brave, William F Maguire, Chana Weinstock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2018
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast CancerAnand Shah, Erik Bloomquist, Shenghui Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2018
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid LeukemiaAviva C Krauss, Xin Gao, Liang Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2024
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal CancerMichael J Fusco, Sandra J Casak, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2020
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Sakar Wahby, Jennifer J Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2024
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, <i>ESR1</i>-Mutated Advanced or Metastatic Breast CancerMirat Shah, Hima Lingam, Xin Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2022
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLCOladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, et al.
Pageof 4